Article Text

Download PDFPDF
The UKCTOCS Experience—Reasons for Hope?
  1. Usha Menon, FRCOG*,
  2. Jatinderpal Kalsi, PhD* and
  3. Ian Jacobs, FRCOG*,
  1. *Gynaecological Cancer Research Centre, Department of Women’s Cancer, Institute of Women’s Health, University College London, London, England; and
  2. Faculty of Medical and Human Science and Manchester Academic Health Science Centre, The University of Manchester, Manchester, England.
  1. Address correspondence and reprint requests to Professor Usha Menon, FRCOG, Gynaecological Cancer Research Centre Maple House, 149 Tottenham Court Road, London W1T 7DN. Email:


Abstract There has been concern about current ovarian cancer screening strategies after the publication showing a lack of benefit from screening in the ovarian part of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. The ongoing United Kingdom Collaborative Trial of Ovarian Cancer Screening involves 202,638 low-risk postmenopausal women. The performance characteristics on prevalence screen in sensitivity, specificity, and stage distribution have been encouraging. Screening differs from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial in the use of algorithms to interpret CA125 and ultrasound imaging and well-defined, centrally coordinated management of screen-detected abnormalities with protocols for intervention based on screening findings. There is a possibility that these essential differences may be sufficient to alter the natural history of ovarian cancer and ultimately lead to demonstration of a mortality benefit from screening when the trial reports in 2014/2015.

  • Ovarian cancer
  • General population screening
  • ROCA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • IJ has a consultancy arrangement with Becton Dickinson in the field of molecular tests and ovarian cancer and a joint holder of a USPTO patent for the ROCA. IJ and UM have a financial interest through UCL Business and Abcodia Ltd in the third party exploitation of clinical trials biobanks which have been developed through the research at UCL. No other declarations. Jatinderpal Kalsi has no conflicts of interest to declare.